Systematic Literature Review of the Economic Burden of Celiac Disease
- 167 Downloads
The prevalence of celiac disease (CD) has rapidly increased over recent decades, but costs related to CD remain poorly quantified.
This systematic review assessed the economic burden of CD in North America and Europe.
MEDLINE, EMBASE, EconLit, and the Cochrane Library databases were systematically searched to identify English-language literature from 2007 to 2018 that assessed costs, cost effectiveness, and health resource utilization for CD.
Forty-nine studies met the inclusion criteria, of which 28 (57.1%) addressed costs of testing and diagnosis; 33 (67.3%) were from Europe. The cost per positive CD diagnosis of testing patients already undergoing esophagogastroduodenoscopy for other indications ranged from 1300 Canadian dollars ($Can) in Canada (2016 value) to €44,712 in the Netherlands (2013 value). Adding the CD test was cost effective when it combined diagnostic modalities (e.g., serology and biopsy). Direct annual excess costs to a US payer per diagnosed CD patient totaled $US6000 (2013 value) more than for a person without CD, chiefly due to outpatient care. Hospitalizations, emergency visits, and medication use were more common with CD. After initiating a gluten-free diet (GFD), patients visited primary care providers less often, used more medications, and missed fewer days from school and work.
Most of the few available economic studies of CD assess testing and diagnosis costs, especially in Europe. Methods of testing generally are considered cost effective when they combine diagnostic modalities in symptomatic patients. Most costs to a payer of managing CD derive from outpatient care. Following GFD initiation, patients lose fewer days from work and school than pretreatment.
We would like to thank Dr Nicole Fusco for careful review of the manuscript.
Guarantor of the article: Dr. Elizabeth Mearns. Authorship contributions: ESM, AT, TB, MG, and DAL contributed to the concept and design of the research study. ESM, TB, and KJC performed the research and collected the data. ESM, TB, and KJC analyzed the data. ESM, TB, and KJC wrote the paper. All authors provided critical analyses of the manuscript drafts and approved the final version of the article.
Compliance with Ethical Standards
ESM, TB, and KJC were/are employees of Truven Health Analytics, an IBM Company, and received a research contract from Takeda Pharmaceuticals International Co. to conduct this study.
Conflict of interest
ESM, TB, and KJC were/are employees of Truven Health Analytics, an IBM Company, and received a research contract from Takeda Pharmaceuticals International Co. to conduct this study. AT, MG, JD, and DAL are employed by Takeda Pharmaceuticals International Co. BL and DSS have served as consultants for Takeda Pharmaceuticals International Co.
Data availability statement
Data-sharing information is not applicable to this study as no datasets were generated or analyzed during the study.
All authors complied with the Committee on Publication Ethics (COPE) guidelines to uphold the integrity of the scientific record.
- 1.Molberg O, McAdam S, Lundin KE, Kristiansen C, Arentz-Hansen H, Kett K, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001;31(5):1317–23. https://doi.org/10.1002/1521-4141(200105)31:5%3c1317:AID-IMMU1317%3e3.0.CO;2-I.Google Scholar
- 4.Lionetti E, Catassi C. The role of environmental factors in the development of celiac disease: what is new? Diseases. 2015;3:282–93.Google Scholar
- 5.Catassi C, Gatti S, Fasano A. The new epidemiology of celiac disease. J Pediatr Gastroenterol Nutr. 2014;59(suppl 1):S7–9. https://doi.org/10.1097/01.mpg.0000450393.23156.59.Google Scholar
- 8.Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology. 2005;128(4 suppl 1):S74–8.Google Scholar
- 12.Hershcovici T, Leshno M, Goldin E, Shamir R, Israeli E. Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. Aliment Pharmacol Ther. 2010;31(8):901–10. https://doi.org/10.1111/j.1365-2036.2010.04242.x.Google Scholar
- 13.Mohseninejad L, Feenstra T, van der Horst HE, Woutersen-Koch H, Buskens E. Targeted screening for coeliac disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. Eur J Health Econ. 2013;14(6):947–57. https://doi.org/10.1007/s10198-012-0441-4.Google Scholar
- 15.Health Quality O. Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(21):1–111.Google Scholar
- 18.Mattila E, Kurppa K, Ukkola A, Collin P, Huhtala H, Forma L, et al. Burden of illness and use of health care services before and after celiac disease diagnosis in children. J Pediatr Gastroenterol Nutr. 2013;57(1):53–6.Google Scholar
- 25.Gili M, Béjar L, Ramírez G, López J, Cabanillas JL, Sharp B. Celiac disease and alcohol use disorders: increased length of hospital stay, overexpenditures and attributable mortality. Rev Esp Enferm Dig. 2013;105(9):537–43.Google Scholar
- 26.Canova C, Pitter G, Ludvigsson JF, Romor P, Zanier L, Zanotti R, et al. Risks of hospitalization and drug consumption in children and young adults with diagnosed celiac disease and the role of maternal education: a population-based matched birth cohort study. BMC Gastroenterol. 2016;16:1. https://doi.org/10.1186/s12876-015-0415-y.Google Scholar
- 27.Roos S, Wilhelmsson S, Hallert C. Swedish women with coeliac disease in remission use more health care services than other women: a controlled study. Scand J Gastroenterol. 2011;46(1):13–9.Google Scholar
- 30.Garrod N, Agbamu J, Barrett C, Holt S. Audit of annual blood tests for children with coeliac disease [abstract no. G235(P)]. Arch Dis Child. 2017;102:A92–3. https://doi.org/10.1136/archdischild-2017-313087.230.Google Scholar
- 31.Johansson K, Malmberg Hård Af Segerstad E, Mårtensson H, Agardh D. Dietitian visits were a safe and cost-effective form of follow-up care for children with celiac disease. Acta Paediatr. https://doi.org/10.1111/apa.14411 (Epub 2018 May 21).
- 40.Herrod PJJ, Lund JN. Random duodenal biopsy to exclude coeliac disease as a cause of anaemia is not cost-effective and should be replaced with universally performed pre-endoscopy serology in patients on a suspected cancer pathway. Tech Coloproctol. 2018;22(2):121–4. https://doi.org/10.1007/s10151-018-1756-7.Google Scholar
- 46.Burger JP, Meijer JW, Wahab PJ. Routine duodenal biopsy to screen for coeliac disease is not effective. Neth J Med. 2013;71(6):308–12.Google Scholar
- 47.Chogle A, Saps M. Yield and cost of performing screening tests for constipation in children. Can J Gastroenterol. 2013;27(12):e35–8.Google Scholar
- 50.Nelsen EM, Lochmann-Bailkey A, Pfau P, Gopal DV, Benson ME. Low yield and high cost of gastric and duodenal biopsies for investigation of symptoms of abdominal pain during routine esophagogastroduodenoscopy [abstract no. 701]. Gastrointest Endosc. 2016;83(5 Suppl 1):AB164.Google Scholar
- 51.Olen O, Gudjonsdottir AH, Browaldh L, Hessami M, Elvin K, Liedberg AS, et al. Antibodies against deamidated gliadin peptides and tissue transglutaminase for diagnosis of pediatric celiac disease. J Pediatr Gastroenterol Nutr. 2012;55(6):695–700. https://doi.org/10.1097/MPG.0b013e3182645c54.Google Scholar
- 52.Sandhu B, Paul S. Should the new ESPGHAN guidelines on diagnosing celiac disease be modified to apply to asymptomatic children? [abstract]. J Pediatr Gastroenterol Nutr. 2016;63(suppl 2):S311–2. https://doi.org/10.1097/01.mpg.0000503536.79797.66.Google Scholar
- 61.Pearson L, Cohn AH, Nicholas F, Smith R. Laboratory testing for celiac disease at the university of vermont medical center: testing practices, utilization, and evidence for a standardized approach to diagnosis. Gastroenterology. 2017;152(5):S223–4.Google Scholar
- 63.Saneian H, Gorgani AM. Diagnostic value of serologic tests in celiac screening. Int J Prev Med. 2012;3(Suppl 1):S58–63.Google Scholar
- 66.Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–60. https://doi.org/10.1097/MPG.0b013e31821a23d0.Google Scholar
- 70.Korponay-Szabo IR, Szabados K, Pusztai J, Uhrin K, Ludmany E, Nemes E, et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ. 2007;335(7632):1244–7. https://doi.org/10.1136/bmj.39405.472975.80.Google Scholar
- 75.Lau MS, Mooney PD, White WL, Rees MA, Wong SH, Kurien M, et al. The role of an IgA/IgG-deamidated gliadin peptide point-of-care test in predicting persistent villous atrophy in patients with celiac disease on a gluten-free diet. Am J Gastroenterol. 2017;112(12):1859–67. https://doi.org/10.1038/ajg.2017.357.Google Scholar
- 76.Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, Chinburapa V. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med. 2008;40(3–4):218–28.Google Scholar
- 78.Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken). 2012;64(11):1649–56. https://doi.org/10.1002/acr.21755.Google Scholar
- 79.American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.Google Scholar
- 81.Department of Health and Social Care, United Kingdom. Published in London, United Kingdom. https://www.gov.uk/government/news/consultation-launched-on-prescribing-of-gluten-free-foods. Accessed 5 May 2017.
- 82.Coeliac Organization United Kingdom. Gluten-free diet and lifestyle: prescriptions. 2018. https://www.coeliac.org.uk/gluten-free-diet-and-lifestyle/prescriptions/. Accessed 12 Jul 2018.
- 84.Malterre T. Digestive and nutritional considerations in celiac disease: could supplementation help? Altern Med Rev. 2009;14(3):247–57.Google Scholar
- 86.Greuter TSA, Frei P, et al. Substantial proportion of celiac disease patients is misleadingly diagnosed based on serology only-diagnostic and therapeutic experience from a real-life setting in Switzerland [abstract]. United Eur Gastroenterol J. 2015;2(Suppl 1):A679.Google Scholar